BR112012026239A2 - polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk - Google Patents

polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk

Info

Publication number
BR112012026239A2
BR112012026239A2 BR112012026239A BR112012026239A BR112012026239A2 BR 112012026239 A2 BR112012026239 A2 BR 112012026239A2 BR 112012026239 A BR112012026239 A BR 112012026239A BR 112012026239 A BR112012026239 A BR 112012026239A BR 112012026239 A2 BR112012026239 A2 BR 112012026239A2
Authority
BR
Brazil
Prior art keywords
alk
resistant
inhibitor
biological sample
resistance
Prior art date
Application number
BR112012026239A
Other languages
English (en)
Portuguese (pt)
Inventor
Liquan Xue
Qin Jiang
Stephan W Morris
Xiaoli Cui
Original Assignee
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital filed Critical St Jude Childrens Res Hospital
Publication of BR112012026239A2 publication Critical patent/BR112012026239A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
BR112012026239A 2010-04-15 2011-04-13 polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk BR112012026239A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/761,050 US8383793B2 (en) 2010-04-15 2010-04-15 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
PCT/US2011/032204 WO2011130340A1 (en) 2010-04-15 2011-04-13 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112012026239A2 true BR112012026239A2 (pt) 2018-06-26

Family

ID=44314994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026239A BR112012026239A2 (pt) 2010-04-15 2011-04-13 polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk

Country Status (10)

Country Link
US (2) US8383793B2 (enExample)
EP (1) EP2558490B1 (enExample)
JP (2) JP6223822B2 (enExample)
KR (1) KR20130064067A (enExample)
CN (1) CN103201286B (enExample)
AU (1) AU2011240636B2 (enExample)
BR (1) BR112012026239A2 (enExample)
CA (1) CA2796306A1 (enExample)
RU (1) RU2012148450A (enExample)
WO (1) WO2011130340A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP3534128A3 (en) 2009-08-13 2020-01-08 Teleflex Life Sciences Unlimited Company Pressure indicator
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
US20130288240A1 (en) * 2010-05-21 2013-10-31 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
AU2012212399B2 (en) 2011-02-02 2015-12-03 Berg, John Improved artificial airway
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
GEP201606560B (en) 2012-03-06 2016-10-25 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
JP6205216B2 (ja) 2012-09-24 2017-09-27 アークレイ株式会社 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
EP3735973A1 (en) 2014-04-10 2020-11-11 Memorial Sloan-Kettering Cancer Center A novel isoform of anaplastic lymphoma kinase and its uses
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
WO2016115480A1 (en) * 2015-01-16 2016-07-21 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
EP3303382A4 (en) * 2015-05-29 2018-12-19 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
EP3368039A1 (en) * 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65987B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN107885972B (zh) * 2016-09-30 2021-07-27 广州华大基因医学检验所有限公司 一种基于单端测序的融合基因检测方法及其应用
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110716042A (zh) * 2019-10-23 2020-01-21 郑州大学 一种用于卵巢癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
CN111235272B (zh) * 2020-01-10 2023-07-07 厦门艾德生物医药科技股份有限公司 一次性检测肺癌多重基因突变的组合物及其应用
TW202206592A (zh) 2020-04-22 2022-02-16 美商艾歐凡斯生物治療公司 用於協調產製供病患特異性免疫治療之細胞的系統和方法
CN112391390A (zh) * 2020-11-19 2021-02-23 山西大学 飞蝗网格蛋白重链基因及其靶向dsRNA的合成与应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE3785591T2 (de) 1986-01-10 1993-09-02 Amoco Corp Kompetitiver homogener test.
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
KR100236506B1 (ko) 1990-11-29 2000-01-15 퍼킨-엘머시터스인스트루먼츠 폴리머라제 연쇄 반응 수행 장치
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
CA2074214C (en) 1991-07-23 2000-02-22 Will Bloch Improvements in the in situ pcr
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994010300A1 (en) 1992-10-30 1994-05-11 The General Hospital Corporation Interaction trap system for isolating novel proteins
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
WO1997039008A1 (en) 1996-04-12 1997-10-23 The Public Health Research Institute Of The City Of New York, Inc. Detection probes, kits and assays
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2000001850A2 (en) 1998-07-02 2000-01-13 Gen-Probe Incorporated Molecular torches
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
DE60014762T2 (de) 1999-05-24 2005-10-13 Tosoh Corp., Shinnanyo Methode zum Nachweis von Ribonukleinsäuren
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2004235747B2 (en) 2003-05-01 2009-05-28 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP2042191B1 (en) * 2007-09-28 2013-01-02 Roberto Chiarle Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
TWI518325B (zh) * 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療

Also Published As

Publication number Publication date
AU2011240636A1 (en) 2012-11-15
EP2558490A1 (en) 2013-02-20
JP2013534804A (ja) 2013-09-09
CN103201286B (zh) 2017-05-03
US20130244893A1 (en) 2013-09-19
CN103201286A (zh) 2013-07-10
EP2558490B1 (en) 2016-12-14
KR20130064067A (ko) 2013-06-17
CA2796306A1 (en) 2011-10-20
JP2017018141A (ja) 2017-01-26
US8383793B2 (en) 2013-02-26
RU2012148450A (ru) 2014-05-20
AU2011240636B2 (en) 2014-10-02
US9458508B2 (en) 2016-10-04
JP6223822B2 (ja) 2017-11-01
WO2011130340A1 (en) 2011-10-20
US20110256546A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
BR112012026239A2 (pt) polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk
Fielder et al. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice
Jones et al. Cardiomyocytes from AKAP7 knockout mice respond normally to adrenergic stimulation
Speyer et al. Cigarette smoking and the pathogenesis of systemic lupus erythematosus
Hu et al. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Liu et al. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Christiansen et al. DNA methylation age is associated with mortality in a longitudinal Danish twin study
Buczkowicz et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
Huang et al. Drp1-mediated mitochondrial abnormalities link to synaptic injury in diabetes model
Wei et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells
Wiklund et al. Macrophage inhibitory cytokine‐1 (MIC‐1/GDF15): a new marker of all‐cause mortality
Consales et al. Exposure to persistent organic pollutants and sperm DNA methylation changes in Arctic and European populations
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
Bitomsky et al. Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death
Eadie et al. ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines
Schennach-Wolff et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients—Is it all about early response?
Davies et al. The role of whole blood impedance aggregometry and its utilisation in the diagnosis and prognosis of patients with systemic inflammatory response syndrome and sepsis in acute critical illness
KR20180018507A (ko) 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
Cornwell et al. Small-molecule inhibition of UBE2T/FANCL-mediated ubiquitylation in the Fanconi anemia pathway
Langlands et al. Chir99021 and Valproic acid reduce the proliferative advantage of Apc mutant cells
Nikonova et al. Nedd9 restrains renal cystogenesis in Pkd1−/− mice
Yin et al. Toxicological assessment of trace β-diketone antibiotic mixtures on zebrafish (Danio rerio) by proteomic analysis
Lavender et al. The interactive role of distress tolerance and eating expectancies in bulimic symptoms among substance abusers
Venkatesan et al. EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms
Carrizzo et al. Nitric oxide dysregulation in platelets from patients with advanced Huntington disease

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05/02/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]